Compare FEAM & SRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FEAM | SRTS |
|---|---|---|
| Founded | 2016 | 2010 |
| Country | United States | United States |
| Employees | 35 | N/A |
| Industry | Major Chemicals | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.4M | 65.5M |
| IPO Year | N/A | 2016 |
| Metric | FEAM | SRTS |
|---|---|---|
| Price | $1.51 | $4.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $6.38 | ★ $6.67 |
| AVG Volume (30 Days) | ★ 207.9K | 39.3K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,482,000.00 |
| Revenue This Year | N/A | $2.00 |
| Revenue Next Year | N/A | $34.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.17 | $3.03 |
| 52 Week High | $7.50 | $5.92 |
| Indicator | FEAM | SRTS |
|---|---|---|
| Relative Strength Index (RSI) | 43.18 | 54.65 |
| Support Level | $1.17 | $3.66 |
| Resistance Level | $2.16 | $4.80 |
| Average True Range (ATR) | 0.17 | 0.27 |
| MACD | 0.03 | 0.05 |
| Stochastic Oscillator | 51.80 | 65.84 |
5E Advanced Materials Inc is an exploration stage company focused on becoming a vertically integrated supplier of specialty boron and boron derivative materials whose mission is to enable decarbonization, increase food security, and ensure domestic supply of critical materials. It has a project located in southern California underpinned by a mineral resource that includes boron and lithium, with the boron being contained in a conventional boron mineral known as colemanite. The company seeks to extract and process the minerals into boric acid, boron materials, lithium carbonate, and potentially other co-products on a commercial scale.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.